OBJECTIVES: Fabry disease is an orphan condition that represents a financial challenge for the Colombian healthcare system. The objective is to determine the comparative costs associated with the treatment and stroke events avoided related to Fabry Disease with agalsidase alfa and agalsidase beta in Colombia,

METHODS: A cost analysis model was developed from the healthcare system perspective for one year of treatment. The two treatment alternatives in this study correspond to agalsidase alfa and agalsidase beta.

The target population used for the analysis was obtained from national public databases and published literature. The costs included were the treatment acquisition, and stroke events associated with FD for year 2019, all obtained from public databases and resources. The clinical data for stroke events was obtained from published literature.

RESULTS: A target population of 1139 patients with FD was calculated. The cost per year treating the FD population with agalsidase alfa was USD $141.137mm whilst that for agalsidase beta was USD $126.71mm. Expected costs per patient due to stroke events included in the simulation were calculated at USD $4,955. The cost of stroke events in the population was 69% (USD$ 503,127) less with agalsidase beta compared to agalsidase alfa.

CONCLUSIONS: The treatment of Fabry Disease orphan condition with agalsidase beta results in the least costly alternative as well as the one with the least stroke events in the population. Both the pricing and the reduction of stroke events and costs related to them, explains the cost differences observed between the alternatives.